Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients

被引:2
|
作者
van der Lee, Manon [1 ]
Sankatsing, Roaj
Schippers, Emile
Vogel, Martin
Faetkenheuer, Erd
van der Ven, Andre
Kroon, Frank
Rockstroh, Juegen
Wyen, Christoph
Baeumer, Anselm
de Root, Eric
Koopmans, Peter
Stroes, Erik
Reiss, Peter
Burger, David
机构
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands
[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[3] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
[4] Univ Med Ctr Leiden, Dept Infect Dis, Leiden, Netherlands
[5] Univ Bonn, Dept Internal Med 1, D-5300 Bonn, Germany
[6] Univ Cologne, Dept Internal Med, Cologne, Germany
[7] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands
[8] Acad Med Ctr, Dept Infect Dis Trop Med & Aids, Amsterdam, Netherlands
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Lopinavir/ritonavir-containing antiretroviral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP450, so no CYP450-based interaction with lopinavir/ritonavir is expected. This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa. Methods: HIV-infected patients on lopinavir/ritonavir (viral load > 400 copies/ml) with total cholesterol (TC) > 6.2 mmol/l were treated with rosuvastatin for 12 weeks, starting on 10 ring once daily. If fasting target values (TC < 5.0 mmol/l, high-density lipoprotein-cholesterol > 1.0 mmol/l, low-density lipoprotein- cholesterol [LDL-c] < 2.6 mmol/l and triglycerides < 2.0 mmol/1) were not reached, rosuvastatin was escalated to 20 mg or 40 mg at week 4 and 8, respectively. Plasma lopinavir/ritonavir trough levels (C-min) were determined at week 0, 4, 8 and 12 and rosuvastatin C-min, at week 4, 8 and 12. Results: Twenty-two patients completed the study. Mean reductions in TC and LDL-c from baseline to week 4 (on rosuvastatin 10 mg once a day) were 27.6% and 31.8%, respectively. Lopinavir/ritonavir concentrations were not influenced by rosuvastatin (P=0.44 and 0.26, repeated-measures analysis). Median (interquartile range) rosuvastatin C-min, for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively. Conclusions: Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, but rosuvastatin levels unexpectedly appeared to be increased 1.6-fold compared with data from healthy volunteers. Until safety and efficacy have been confirmed in larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be used with caution.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 50 条
  • [21] Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
    Merry, C
    Barry, MG
    Mulcahy, F
    Ryan, M
    Heavey, J
    Tjia, JF
    Gibbons, SE
    Breckenridge, AM
    Back, DJ
    AIDS, 1997, 11 (04) : F29 - F33
  • [22] Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients
    Escobar, Ismael
    Pulido, Federico
    Perez, Esther
    Arribas, Jose Ramon
    Garcia, Maria del Pilar
    Hernando, Asuncion
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (08): : 490 - 494
  • [23] Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children
    Puthanakit, Thanyawee
    van der Lugt, Jasper
    Bunupuradah, Torsak
    Ananworanich, Jintanat
    Gorowara, Meena
    Phasomsap, Chayapa
    Jupimai, Thidarat
    Boonrak, Pitch
    Pancharoen, Chitsanu
    Burger, David
    Ruxrungtham, Kiat
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (05) : 1080 - 1086
  • [24] The Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Minitab Sprinkles, Tablets, and Syrups in African HIV-Infected Children
    Musiime, Victor
    Fillekes, Quirine
    Kekitiinwa, Adeodata
    Kendall, Lindsay
    Keishanyu, Rosette
    Namuddu, Rachel
    Young, Natalie
    Opilo, Wilfred
    Lallemant, Marc
    Walker, A. Sarah
    Burger, David
    Gibb, Diana M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (02) : 148 - 154
  • [25] Small dense LDL in HIV-infected patients treated with lopinavir/ritonavir or atazanavir
    Richter, W. O.
    Berger, F.
    Mauss, S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 401 - 401
  • [26] Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients
    Merry, C
    Barry, MG
    Mulcahy, F
    Tjia, JF
    Halifax, KL
    Heavey, J
    Kelly, C
    Back, DJ
    AIDS, 1998, 12 (03) : 325 - 327
  • [27] Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics
    Boffito, M
    Arnaudo, I
    Raiteri, R
    Bonora, S
    Sinicco, A
    Di Garbo, A
    Reynolds, HE
    Hoggard, PG
    Back, DJ
    Di Perri, G
    AIDS, 2002, 16 (15) : 2081 - 2083
  • [28] Effect of Lopinavir/ritonavir protease inhibitor on the pharmacokinetics of Irinotecan in HIV-infected patients with advanced Kaposi's sarcoma.
    Corona, G.
    Vaccher, E.
    Di Gennaro, G.
    Tirelli, U.
    Toffoli, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 534S - 534S
  • [29] Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Zhu, Li
    Liao, Shanmei
    Child, Michael
    Zhang, Jenny
    Persson, Anna
    Sevinsky, Heather
    Eley, Timothy
    Xu, Xiaohui
    Krystal, Mark
    Farajallah, Awny
    McGrath, Donnie
    Molina, Jean-Michel
    Bertz, Richard
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (02) : 465 - 468
  • [30] Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
    Zhang, Chao
    McIlleron, Helen
    Ren, Yuan
    van der Walt, Jan-Stefan
    Karlsson, Mats O.
    Simonsson, Ulrika S. H.
    Denti, Paolo
    ANTIVIRAL THERAPY, 2012, 17 (01) : 25 - 33